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ABSTRACT
Approximately 15-20% of ovarian cancer patients receiving platinum-based
chemotherapy are primary platinum-resistant. Identification of these patients and
transfer to other more effective therapy could reduce the morbidity of ovarian cancer.
ERCC1 is a DNA repair gene which can complex with XPF to repair cisplatin-induced
DNA damage and cause chemotherapy resistance. In this study, we found a novel
ERCC1 transcript initiated upstream of the normal transcription initiation site. The
expression of this larger ERCC1 transcript dramatically increased following cisplatin
treatment in ovarian cancer cells and was regulated by the MAPK pathway. This
phenomenon conferred enhanced cisplatin resistance on ovarian cancer cells, and
was confirmed with chemosensitive and chemoresistant patients’ samples. Our
data suggested that larger ERCC1 transcript levels correlated with the outcome of
platinum-based chemotherapy.

investigate the underlying mechanisms of chemotherapy
resistance and to identify the patients who are resistant to
traditional platinum-based chemotherapy to redirect them
to alternative therapy.
Nucleotide excision repair (NER) mechanisms
are used in the repair of DNA lesions including those
produced by chemotherapeutic agents [6]. NER has been
strongly linked to cisplatin resistance [7]. Excision repair
cross complementation group-1 (ERCC1) is one of the
critical genes in NER pathway [8]. The gene for ERCC1 is
located on chromosome 19q13.2-q13.3 and has 10 exons
spread over 15kb of the genome [9]. It forms a heterodimer with XPF to incise the 5’ side of the DNA lesion [10,
11]. A number of studies have correlated ERCC1 levels
with DNA repair capacity [12–14]. Higher expression

INTRODUCTION
Epithelial ovarian cancer (EOC) is the leading cause
of death from gynecologic malignancies in the world [1].
The first line therapy for ovarian cancer patients is usually
traditional surgery followed by combination platinumbased chemotherapy which may result in complete clinical
remission in up to 75% of cases [2]. Most of platiumsensitive patients will eventually become refractory to the
treatment. All recurrent ovarian cancer patients develop
platinum-resistance over time in terms of secondary
platinum-resistance [3]. The remaining 15-20% of patients
will however not respond to the initial chemotherapy
[4]. Currently, there is no reliable diagnostic biomarker
for the resistant patients [5]. Thus, it remains urgent to
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level of ERCC1 reduced the sensitivity of ovarian cancer
[15] and other cancers [16] to cisplatin. However, the
clinical relevance of ERCC1 as potential predictor for
platinum-resistance has been very controversy been
discussed in the past in general, especially with regard to
immunohistochemical ERCC1 protein detection [17].
Epigenetic changes and alternative splicing of
specific genes allow cancer cells to become resistant to
chemotherapeutic drugs [18]. ERCC1 gene has several
types of transcript variants [19]. A 42-bp spliced sequence
in the 5’-UTR of ERCC1 gene has been shown to influence
the response of ovarian cancer to cisplatin therapy [20].
ERCC1 exon VIII alternative splicing can also regulate
cisplatin-resistance in ovarian cancer [21]. These data
suggest that ERCC1 transcript variants may influence the
sensitivity of ovarian cancer to chemotherapy.
The MAPK pathway has an important role in
regulation of cell differentiation and growth [22]. It has
been reported that ERK, one of the kinases in the MAPK
pathway, was activated in response to a series of DNAdamaging agents, including cisplatin [23]. Previous
studies also indicated that MAPK pathway regulated
ERCC1 expression by epidermal growth factor [24]. In

addition, cisplatin-induced ERCC1 expressions decreased
by blocking ERK activation in lung cancer cell lines [25].
Therefore, we suspected that cisplatin could induce Larger
ERCC1 expression by the MAPK pathway.
In this study, we identified a novel ERCC1 transcript
in ovarian cancer cells, originating from upstream of
normal ERCC1 transcriptional start site and investigate its
role in platinum-based chemotherapy.

RESULTS
A novel larger ERCC1 transcript variant in
ovarian cancer cells
Previous study showed that a larger ERCC1
transcript encoded ERCC1 protein in mice and this novel
transcript originated from an upstream promotor [26]. No
such transcript has however been clearly demonstrated in
human cells. We, therefore investigated the larger ERCC1
transcript in human ovarian cancer cell A2780 by RTPCR. Several novel forward primers located upstream of
the normal human ERCC1 initiation site were designed as
shown in Figure 1A. If novel ERCC1 transcripts originating

Figure 1: An upstream ERCC1 transcript in human cell lines. (A) Schematic of human ERCC1 gene showing the exons, location

of the normal transcription initiation site (green arrow), transcriptional start site (blue arrow) and presumed location of the upstream
initiation site (red arrow). The positions of primers used to detect all ERCC1 transcripts (T) and predicted sizes of PCR products are
indicated. The positions of the various primers used to detect the upstream ERCC1 transcripts (U) and predicted size of PCR products are
also indicated. (B) RT-PCR of mRNA extracted from human ovarian cancer A2780 cells. All ERCC1 transcripts were detected with primer
pair of Hexon1A and H-exon 2-3. ERCC1 transcripts initiating upstream were detected with primer pairs of hskin2RT, hskin3RT, hskin4RT,
hskin5RT and H-exon2-3.
www.impactjournals.com/oncotarget
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upstream existed, these primers in combination with reverse
primer H-exon 2-3, which is located in ERCC1 exon 2,
should generate PCR products from 291bp to 419bp. Our
data showed that two bands, 42bp apart, were detected
with all primer pairs. Two separated bands were generated
by alternative splicing of a 42bp region in ERCC1 exon1
which has been reported previously [27]. The sizes of the
gel bands with the different primer pairs agreed with our
prediction (Figure 1B). This indicated that the novel larger
ERCC1 transcript originating upstream of ERCC1 existed
in human ovarian cancer cells. We have also observed the
presence of the larger ERCC1 transcript in other human
cells such as melanoma, keratinocyte and fibroblast cells

(Data not shown). This novel ERCC1 transcript may
therefore not be specific to ovarian cancer cells.
To map the 5’ end of this larger ERCC1 variant,
we performed 5’ RACE assay on the ovarian cancer
cells using the ERCC1 specific reverse primers from
upstream of the normal transcriptional start site. The 5’
RACE sequencing results showed that ERCC1 5′ RACE
endpoints determined on the mRNA of human ovarian
cells were much further upstream than the normal
transcriptional start site. The sequences of 20 independent
5′ RACE clones are shown in Figure 2 aligned alongside
mouse larger ERCC1 5′ RACE sequence [28], the human
and mouse genomic DNA sequence. The endpoint of the

Figure 2: Start points of human ERCC1 larger transcript by 5′ RACE. The sequence of the longest 5′ RACE clone determined

using human ovarian cancer cell line A2780 is shown, aligned against the mouse larger ERCC1 5′ RACE sequence, human and mouse
genomic DNA sequence. The sequence is numbered from the normal translation start site in light blue, with intron 1 and 42bp spliced
sequence omitted. The start points of the human larger ERCC1 5′ RACE clones are indicated in red. The start points of the mouse larger
ERCC1 5′ RACE clones are indicated in purple. The Hskin 4RT REV and REV1 primers used in our 5′ RACE assay are indicated in green.
TSS, normal human transcription start site is shown in yellow at -152bp.
www.impactjournals.com/oncotarget
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longest clone mapped to -602bp upstream of the normal
transcriptional start site (Figure 2).

cancer cells (Figure 3C). All together, cisplatin treatment
induced a time- and dose- dependent larger ERCC1
increase in ovarian cancer cells. Larger ERCC1 expression
may be related to cisplatin resistance in ovarian cancer
cells.
To further investigate the relationship between
the larger ERCC1 transcript and cisplatin resistance, the
expressions of the larger ERCC1 transcript following
cisplatin treatment in platinum-sensitive ovarian cancer
cells PEO14 and A2780 and normal ovarian epithelial
cells ISOE80 were examined. Cisplatin treatment
induced approximately 5.3-fold and 2.6-fold increase in
larger ERCC1 mRNA expression in ovarian cancer cells
PEO14 and A2780 respectively (Figure 4A). However,
the expression of the larger ERCC1 transcript in normal
epithelial ovarian cells IOSE80 was not significantly
affected by cisplatin (Figure 4A). In addition, the ratios of
larger ERCC1 to total ERCC1 mRNA following cisplatin
treatment in ovarian cancer cells PEO14 and A2780
indicated increases from 41% to 98% and 54% to 79%
respectively (Figure 4B). However, the relative abundance

Cisplatin induces the expression of larger
ERCC1 in ovarian cancer cells
The expression of larger ERCC1 following cisplatin
treatment was examined by quantitative real-time PCR
(Figure 3). Larger ERCC1 expression was induced by
cisplatin (0, 3, 6, 9 or 12 μM) and the peak was 2.8-fold
compared to the control group at 6 μM. Our data also
indicated that the expression of larger ERCC1 timedependently increased following cisplatin treatment (6
μM) (Figure 3B). The peak was 3.5-fold compared to
the control group at 72 h. Although the LERCC1 mRNA
expression peak of the survival cells was at 72h, most of
cells were dead because of the hyper toxicity of cisplatin.
Therefore, we determined to treat cells with cisplatin (6
μM) for 48 h in the following experiments. Similar to
the transcriptional data, our data indicated that cisplatin
treatment induced ERCC1 protein expression in ovarian

Figure 3: Cisplatin induces the expression of larger ERCC1 in ovarian cancer cells. (A) A2780 cells were treated with

cisplatin (0, 3, 6, 9 or 12 μM) for 24 h. Quantitative real-time PCR assay showed mRNA level of larger ERCC1 after cisplatin treatment.
(B) A2780 cells were treated with cisplatin (6 μM) for 24 h, 48 h or 72 h. Quantitative real-time PCR assay showed mRNA level of larger
ERCC1 following cisplatin treatment at different time point. (C) A2780 cells were treated with cisplatin for 48h. Western blot showed
protein level of ERCC1 after cisplatin treatment. A2780 cells were treated with cisplatin (6 μM) for 24 h, 48 h or 72 h. Western blot showed
protein level of ERCC1 following cisplatin treatment at different time point. Three independent experiments were performed. Student’s
t-test, * p<0.05, ** p<0.01, *** p<0.001.
www.impactjournals.com/oncotarget
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Overexpression of larger ERCC1 transcripts
enhance cisplatin resistance

of larger ERCC1 in normal ovarian epithelial cells
ISOE80 decreased slightly following cisplatin treatment
(Figure 4B). It suggested that cisplatin selectively induced
the expression of the larger ERCC1 transcript in ovarian
cancer cells.
Moreover, we compared the expression of larger
ERCC1-transcript between platinum-sensitive A2780
cells and platinum-resistant A2780/DDP cells (Figure
4C). The expression of larger ERCC1 was much higher
in A2780/DDP cells than in A2780 sensitive cells. It was
suggested that larger ERCC1 transcript was possible to be
stably up-regulated in platimum-resistant lines. Our data
also indicated that cisplatin induced the larger ERCC1
transcript in platinum-sensitive A2780 cells but not
significantly affect that in platinum-resistant A2780 cells.
We considered that the resistant cells might originally
express high level of larger ERCC1 transcript and leave
little increase space.

To further investigate the roles of larger ERCC1
on chemotherapy resistance in ovarian cancer, A2780
cells were transfected with plasmids containing the larger
ERCC1 transcript, wild-type ERCC1 or empty plasmid as
the negative control. The larger or total ERCC1 mRNA
expression in transfected cells significantly increased
compared to the negative control (Figure 5A). The ERCC1
protein level was also elevated by either the larger or wildtype ERCC1 transfection (Figure 5B). MTT and colony
formation assay demonstrated that overexpression of the
larger or wild-type ERCC1 similarly increased resistance
to cisplatin-mediated growth inhibition. However,
pcDNA3.1-Larger ERCC1 transfected cells were more
resistant to cisplatin treatment than pcDNA3.1-ERCC1
transfected cells (Figure 5C and 5D). Based our data, the

Figure 4: Comparison of the larger ERCC1 expression by cisplatin in different ovarian cells. (A) Ovarian normal cells

ISOE80, ovarian cancer cells PEO14 and A2780 were untreated, or treated with cisplatin (6 μM) for 48 h. Histogram shows the mean level
(± SD) of larger ERCC1 mRNA relative to β-Actin determined from three independent experiments by qRT-PCR. Data were normalized to
the mean level of larger ERCC1 relative to β-Actin in the controls. (B) Histogram shows the ratio (± SD) of larger ERCC1 mRNA relative
to total ERCC1 mRNA determined from three independent experiments by qRT-PCR. Larger ERCC1 mRNA and total ERCC1 mRNA
levels were each calculated relative to β-Actin. (C) Platinum-sensitive ovarian cancer cells A2780 and platinum-resistant A2780/DDP were
untreated, or treated with cisplatin (6 μM) for 48 h. Histogram shows the mean level (+ SD) of larger ERCC1 mRNA relative to β-Actin
determined from three independent experiments by qRT-PCR. Data were normalized to the mean level of larger ERCC1 relative to β-Actin
in the A2780 control. Student’s t-test, * p<0.05, ** p<0.01, *** p<0.001.
www.impactjournals.com/oncotarget
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novel larger ERCC1 transcript maybe the main ERCC1
transcript involved in the regulation of ovarian cancer cells
resistance to chemotherapy.

repair capacity of the larger ERCC1 compared to the
conventional ERCC1, we detected the expression of
phosphorylated H2AX (γ-H2AX) which was an early
response to DNA damage and considered as a marker
of double strand break. Compared to the conventional
ERCC1, overexpression of Larger ERCC1 could more
effectively reduced cisplatin induced DNA damage
(Figure 6).

Overexpression of larger ERCC1 transcripts
decreased DNA damage caused by cisplatin
Larger ERCC1 could have a stronger influence
on platinum-resistance. To further detect the DNA-

Figure 5: Overexpression of the larger ERCC1 transcript induced the resistance to cisplatin. A2780 cells were transfected

with either pcDNA3.1-LERCC1, pcDNA3.1-ERCC1 or pcDNA3.1 vector as the negative control (NC). (A) The expression of the larger or
total ERCC1 mRNA was detected by qRT-PCR. Histogram showed mean levels (+ SD) of the larger or total ERCC1 mRNA against β-Actin.
(B) The expression of ERCC1 protein was detected by Western blotting. Histogram showed the levels of ERCC1 relative to β-Actin. (C)
The cells were treated with cisplatin (6 μM) for 48 h. The cells' viability was detected by MTT assay and expressed relative to that of nontransfected cells. (D) The cells were treated with cisplatin (2 μM) for 15 days. The surviving colonies were stained and counted. The colony
numbers were counted and the colony formation ratio was calculated according to the formula: Colony formation ratio (%) = (number of
colonies/number of cells seeded)×100. Three independent experiments were performed.* P<0.05, ** P<0.01, *** P<0.001, Student’s t-test.
www.impactjournals.com/oncotarget
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Expression of larger ERCC1 is regulated by the
MAPK pathway

Expression of larger ERCC1 transcript
correlates with platinum chemotherapy
responses in ovarian cancer patients

Many studies have demonstrated an activation of
the MAPK pathway in response to cisplatin treatment
[29, 30]. Our previous study also indicated that ERCC1
induction by cisplatin was dependent on the MAPK
pathway in melanoma cells [31]. Therefore, we probed
whether the MAPK pathway activation was responsible
for induction of the larger ERCC1 transcript in ovarian
cancer cells following cisplatin treatment. A specific
inhibitor of MEK1/2, PD0325901, which is highly
selective in preventing ERK activation, was used to
evaluate the relationship between the MAPK pathway
and the larger ERCC1 induction (Figure 7A). We noticed
that the larger ERCC1 transcription expression or the
ratios of larger ERCC1 relative to total ERCC1 mRNA
following cisplatin treatment was efficiently inhibited by
the MEK inhibitor (Figure 7B). Our western-blotting data
also showed that blocking the MAPK pathway lead to
reduction of ERCC1 protein induced by cisplatin (Figure
7C). Thus ERK activation may play an important role in
the regulation of larger ERCC1 induction by cisplatin in
ovarian cancer cells.

The clinical and pathological characteristics of
the subjects in our cohort are shown in Table 1. Of
the 23 patients, 16 were chemosensitive and 7 were
chemoresistant. The larger ERCC1 transcript and total
ERCC1 mRNA expression levels (normalized to β-actin as
internal control) in ovarian cancer tissues of these patients
were evaluated by real-time PCR. Our data showed that
the total ERCC1 mRNA expression levels were similar
in chemosensitive and chemoresistant patients (P=0.1923,
Figure 8A). However, the expression of larger ERCC1 was
significantly higher in the chemoresistant group compared
to chemosensitive group (P=0.0003, Figure 8B).

DISCUSSION
Cisplatin is one of the most widely used
chemotherapeutic agents for the treatment of ovarian
cancer [32]. However, the efficacy of cisplatin is hampered
by resistance of ovarian cancer cells to its cytotoxicity
[33]. ERCC1 plays an important role in recognizing and

Figure 6: Overexpression of larger ERCC1 transcripts decreased DNA damage caused by cisplatin. (A) DNA damage in
A2780 cells was examined by Immunofluorescence staining. The cells were transfected with pcDNA3.1-LERCC1, pcDNA3.1ERCC1 or pcDNA3.1 vector as the negative control (NC), and then examined for γ-H2AX foci formation and expression
following cisplatin (6 μM, 48 h) treatment. (B) IF analysis of γH2AX foci in nuclei of cells (n = 30) by Image J software in
three independent assays. Student’s t-test, * p<0.05, ** p<0.01, *** p<0.001.
www.impactjournals.com/oncotarget
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Figure 7: Expression of the larger ERCC1 transcript is regulated by the MAPK pathway. Ovarian cancer cells A2780 and

PEO14 were either untreated or treated with cisplatin (6 μM), or treated with both cisplatin and MEK inhibitor PD0325901 (1 μM) for 48h.
The MEK inhibitor was added 30 min before cisplatin treatment. (A) Histogram shows the mean level (+ SD) of larger ERCC1 relative to
β-Actin determined from three independent experiments by qRT-PCR. Data were normalized to the mean level of larger ERCC1 relative
to β-Actin in the controls. (B) Histogram shows the mean ratio (+ SD) of larger ERCC1 mRNA over total ERCC1 mRNA determined
from three independent experiments by qRT-PCR. Larger ERCC1 mRNA and total ERCC1 mRNA levels were each calculated relative to
β-Actin. (C) Western blot showing protein levels of ERCC1 in A2780 cells treated with cisplatin (6 μM) or both cisplatin and PD0325901
(1 μM) for 48h. Histogram showing mean level of ERCC1 expression from three independent experiments after treatment. ** P < 0.01;
*** P < 0.001, Student’s t-test.

Figure 8: Comparison of normal and larger ERCC1 transcript expression in chemoresistant and chemosensitive
patients’ specimen. Expression of normal and larger ERCC1 transcript from twenty-three ovarian cancer patients were detected by

qRT-PCR. Seven were from chemoresistant patients and sixteen were from chemosenstive patients. (A) Expression of total ERCC1 mRNA
relative to β-actin inchemoresistant group and chemosenstive group, P=0.1923, Mann-Whitney test. (B) Expression of larger ERCC1
mRNA relative to β-actin in chemoresistant group and chemosenstive group, P=0.0003, Mann-Whitney test.
www.impactjournals.com/oncotarget
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Table 1: Clinical characteristics
Characteristic n=23

Drug sensitivepatients
(n=16)

Drug resistantpatients(n=7)

Age (years)

0.819

Median

57.5

52

Range

48-73

45-68

FIGOstage

0.45

I-II

3 (19)

0 (0)

III-IV

13 (81)

7 (100)

Grade

0.514

1

6 (38)

3 (43)

2

0 (0)

1 (14)

3

4 (24)

0 (0)

ND

6 (38)

3 (43)

Histologic subtype
Serous adenocarcinoma

p Value

0.358
15 (94)

6 (86)

Mucinous adenocarcinoma

0 (0)

0 (0)

Endometrioid
adenocarcinoma

0 (0)

0 (0)

Mixed serous mucinous
cystadenocarcinoma

1 (6)

1 (14)

CA125 at diagnosis(U/ml)

<0.001

Median

821

1404

Range

26-2169

1032-4648

Data was analyzed by Chi-square test.
FIGO international federation of gynecology and obstetrics, ND not determined.

removing cisplatin- induced DNA adducts and so repairs
DNA lesions [34]. Previous study has identified a novel
1.5kb mouse ERCC1 transcript [28]. This novel transcript
originated from about 400bp upstream of the normal Ercc1
promoter [30]. However, whether similar novel transcripts
existed in human ovarian cells, and the potential functions
are yet to be clarified.
In the present study, we have showed that the larger
ERCC1 transcript also existed in human ovarian cell lines.
The ERCC1 5′RACE endpoints determined on the RNA
of human ovarian cell lines were mapped to around 600bp
upstream of the normal transcriptional start site. This
novel transcript is similar to the novel ERCC1 transcript
in mouse skin which mapped to 400bp upstream of the
normal transcriptional start point [30]. Whether there is
another promoter that regulates the expression of this
novel larger ERCC1 needs further investigation.
ERCC1 levels influence DNA repair capacity
and associate with cellular resistance to cisplatin [35,
www.impactjournals.com/oncotarget

36]. The observation that the ratios of larger ERCC1
relative to total ERCC1 mRNA significantly increased
in ovarian cancer cells but not normal cells following
cisplatin treatment implied cisplatin may preferentially
induce the expression of larger ERCC1 rather than the
regular transcript in ovarian cancer cells. In addition, we
found platinum-resistant cells stably over-expressed the
larger ERCC1 transcript compared to sensitive cells. All
together, our data suggested that the novel larger ERCC1
transcript may be related to cellular resistance to cisplatin
for ovarian cancer patients.
Further investigations on the functions of the larger
ERCC1 transcript indicated that overexpression of the
larger ERCC1 transcript in ovarian cancer cells could
increase cell viability and stimulate colony formation to
protect ovarian cancer cells from cisplatin induced DNA
damage. The expression of larger ERCC1 transcript
has stronger influence on drug sensitivity and behavior
of ovarian cancer cells in response to cisplatin (Figure
85767
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Table 2: All primers used for 5’ RACE assay
Name
H-exon 2-3 reverse
Hskin4RT
reverse
REV1
Oligo dT anchor
PCR anchor

Sequence 5'-3'

Description

ATTTGTGATACCCCTCGACGAG

Normal human ERCC1 transcript
reverse primer

TGTACAGAGATCGCCCTGCTCTATGC

Larger Human ERCC1 transcript
reverse primer

CGGTCCTCCAGAACCATAGA

Larger Human ERCC1 transcript
reverse primer

GACCACGCGTATCGATGTCGACTTTTTTTTTTTTTTTTV
Anchor primer
(V=A, C or G)
GACCACGCGTATCGATGTCGA

5C and 5D). This could be due to a slightly better gene
turnover of larger ERCC1 (enhanced translation and/
or reduced degradation) compared to normal ERCC1.
Moreover, our data revealed that overexpression of larger
ERCC1 could more effectively reduced cisplatin induced
DNA damage than the conventional ERCC1 (Figure 6).
Based on these data, it suggested that cisplatin selectively
induced the larger ERCC1 expression which contributed
to trigger drug resistance.
ERK1/2 is one of the important kinases in the
MAPK pathway that regulates cell growth and death,
and has been shown to be activated in response to DNA
damage agents, including UV radiation, ionizing radiation,
alkylating agents and cisplatin [37]. Previous studies have
shown that ERCC1 induction by cisplatin was dependent
on the MAPK pathway [31] and that blocking ERK1/2
activation decreased cisplatin-induced ERCC1 protein
levels in lung cancer and melanoma cell lines [38]. Our
data was in agreement with these observations (Figure
7) and thus suggests the induction of larger ERCC1 by
cisplatin to be, at least, through the MAPK regulatory
pathway. However, how this pathway might preferentially
enhance larger ERCC1 expression upon cisplatin treatment
is yet to be deciphered.
Previous studies investigating the relationship
between ERCC1 expression and clinical outcomes of
platinum-based chemotherapy in ovarian cancer have
yielded conflicting results. Some suggest prognostic
value of ERCC1 in ovarian cancer [36, 39], whereas
others express limited clinical significance of the gene
in primary ovarian cancer patients [40, 41]. In support
of the latter view, we have demonstrated that the larger
ERCC1 transcript level but not total ERCC1 is possible
to correlate with the sensitivity of ovarian cancer patients
to platinum-based chemotherapy (Figure 8). However, we
admitted that limitation of the small clinical sample size in
this study. We will further explore these results with largesample-size pharmacological study in the future.
In conclusion, our study identified a novel larger
ERCC1 transcript originating from upstream of the normal
www.impactjournals.com/oncotarget

Internal anchor primer

ERCC1 transcriptional start point. This larger ERCC1
transcript was induced by cisplatin treatment through the
MAPK pathway. More importantly, the larger ERCC1
transcript enhanced ovarian cancer cells resistance to
cisplatin treatment. Thus larger ERCC1 transcript levels
may correlate with the outcome of platinum-based
chemotherapy.

MATERIALS AND METHODS
Cell lines and reagents
Human ovarian cancer cells A2780 and A2780/DDP
were obtained from the American Type Culture Collection
(ATCC) and PEO14 was kindly provided by Dr. Charlie
Gourley (Edinburgh, UK). Both ovarian cancer cell lines
were cultured in Dulbecco's modified Eagle's medium
(DMEM) complete medium, supplemented with 10% fetal
bovine serum (FBS). Normal ovarian epithelial cell line
IOSE80 was obtained from Canadian Ovarian Tissue Bank
and grown in medium 199 (Invitrogen) and MCDB 105
(Sigma), supplemented with 10% FBS. Rabbit anti-human
ERCC1 and β-actin polyclonal antibodies were purchased
from Proteintech Group lnc. (Chicago, USA). Cisplatin
was purchased from Sigma (St. Louis, MO, USA) and
MEK inhibitor PD0325901 was obtained from Selleck
(St. Louis, MO, USA). Antibody against γH2AX was
purchased from Cell Signaling Technology (MA, USA).
Antibody against ERCC1 was purchased from Santa Cruz
(CA, USA).

Tissue collection
Twenty-three surgically resected primary epithelial
ovarian cancer samples were collected in accordance with
The Code of Ethics of the World Medical Association
during the period of 2016 to 2017 at the Affiliated
Cancer Hospital of Zhengzhou University. Diagnosis of
ovarian cancer was evaluated by pathologists. The Ethical
Research Committee of Affiliated Cancer Hospital of
85768
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5′ RACE assay

Zhengzhou University approved the protocol of this study.
All patients formally and voluntarily gave their consent
for the study. All patients underwent debulking surgery
and subsequent platinum-based chemotherapy. Baseline
characteristics and serum CA125 levels were collected.
All patients had a follow up ≥ 12 months by serum CA125
and documentation of lesion progression or appearance
of new lesions on CT-scan. Chemotherapy resistance
or sensitivity was defined as the presence or absence of
tumor relapse progression within 6 months, or 6 months
after completion of prior platinum-based chemotherapy.
Patient characteristics are listed in Table 1. The data were
analyzed anonymously.

Characterization of the 5′ end of the human larger
ERCC1 transcript was exerted using 5′/3′ RACE kit
(Roche) following the manufacturer’s instruction. In
brief, the first strand cDNA was synthesized from total
RNA using an ERCC1-specific primer H exon 2-3
with deoxynucleotides and reverse transcriptase. The
synthesized cDNA was then purified by High Pure PCR
Product kit (Roche) and a homopolymeric A-tail was
added to the 3′ end of the cDNA. The tailed cDNA was
PCR amplified using a second ERCC1-specific primer
Hskin 4RT REV in combination with oligo dT-anchor
primer. To further amplify this cDNA, a further round
of nested PCR was performed using the internal primers
PCR-anchor and REV1. The PCR products were separated
by 1.5% agarose gel and cloned into p-GEM T-EASY
vector for sequencing analysis. All primers used for 5’
RACE assay are mentioned in Table 2.

RNA isolation
Total RNA was extracted from cells or human tissues
using Trizol reagent (Life technologies, California) or
Magnetic Total RNA kit (GenePharma, China) according
to the manufacturer’s instructions. In briefly, cut 2-5
paraffin sample sections between 5-10 μm. Immediately
place the sections into the 1.5 ml microcentrifuge
tube. Incubate at 80°C for 15 min to melt the paraffin.
Immediately centrifuge at 13,000 x g for 5 min. Add 400 μl
RNA Wash Buffer II. Resuspend the Mag-Bind thoroughly
by vortexing for 20 sec or pipetting up and down 10-20
times. Place the tube onto the magnet separation device to
magnetize the Mag-Bind. Aspirate and discard the cleared
supernatant. Remove any liquid drops from tube. Add
73.5 μl DNase I Digestion Buffer and RNase-free DNase
I to each sample. Resuspend the Mag-Bind thoroughly by
vortexing for 20 sec or pipetting up and down 10-20 times.
Incubate at 37°C for 15 min. Add 225 μl GFC Buffer. Mix
thoroughly by vortexing for 20 sec or pipetting up and
down 10-20 times. Place the tube onto a magnet separation
device to magnetize the Mag-Bind. After 3-5 min aspirate
and discard the cleared supernatant. Remove the tube from
the magnetic separation device. Air dry the Mag-Bind by
leaving the tubes on the magnetic separation device for 10
min. Transfer the cleared supernatant containing purified
RNA into a new nuclease-free 1.5 ml microcentrifuge
tube. Store the purified RNA at -80°C.

Real time PCR analysis
Real-time
quantitative
polymerase
chain
reactions were used to quantify the cDNAs of interest
using Taqman® Gene Expression Assay and Applied
Biosystems 7900HT Fast Real-Time PCR System.
Real-time quantitative polymerase chain reactions were
prepared in a 20 μl volume containing 1ul specific 20X
Taqman Gene Expression Assay, 10 ul 20X Taqman
Gene Expression Master Mix, 4ul cDNA template (10100 ng), and 5ul RNase-free water. Routine real-time
quantitative polymerase chain reaction conditions were:
AmpliTaq Gold Enzyme activation at 95°C for 10 min,
then 40 cycles of DNA denaturation at 95°C for 10 min,
primer annealing and DNA polymerase extension at 60
°C for 60 sec. The primer sequence for the larger ERCC1
transcript was 5'-CTGGGAATTTGGCGACGTAA-3' and
5'-ATGGATGTAGTCTGGGTGCAG-3'.

Expression vector construction and transfection
cDNAs were reverse-transcribed using TransScript
Taq reverse transcriptase and Random primers. The
larger and normal ERCC1-coding region were amplified
by polymerase chain reaction (PCR). The PCR products
were cloned into the constitutive mammalian expression
vector pcDNA3.1 containing neomycin selectable
marker. A2780 cells were transfected with pcDNA3.1larger ERCC1, pcDNA3.1-ERCC1 or pcDNA3.1 vector
as the negative control using a Lipofectamine 2000
Transfection Reagent (Invitrogen, USA) according to
the manufacturer’s protocol. Stable transformants were
selected by 500μg/ml G418 (Sigma, USA) treatment.
Selection pressure was removed after pools of transfected
colonies were isolated.

RT-PCR
The RT-PCR was performed in 50 μl reaction
containing 0.5 pmol/ul primers, 0.25 mM dNTPs, 2.5 mM
MgCl2, 100 ng cDNA template, 1U Taq DNA polymerase
(Promega), and Taq PCR buffer (Promega). PCRs were
carried out by DNA denaturation at 94°C for 5 min, followed
by 30 cycles of DNA denaturation at 94°C for 1 min, primer
annealing at 50 °C for 1 min and DNA polymerase extension
at 72 °C, with a final extension of PCR products at 72°C for
5 min after cycling. All forward and reverse primers used for
RT-PCR are mentioned in Table 2.
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Western blot analysis

square test was used to analyze the clinical characteristics by
SPSS version 14.0 (SPSS, Chicago, IL, USA). Values of P <
0.05 were considered statistically significant.

Cells were harvested and lysed in cold RIPA buffer
and quantitated. Proteins were separated by 10% SDSPAGE and transferred onto nitrocellulose membrane
using a semi-dry transfer apparatus for 40min. The
membrane was blocked with 5% non-fat milk for 1h
and then incubated with the specific primary antibody
solution overnight at 4ºC. Signal was detected using HRPconjugated secondary antibodies and visualized by ECL
(Thermo Scientific, USA).
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